Facts About IPF
IPF is a debilitating and fatal lung disease.
Search
The Supplier Code of Conduct
BI’s expectations towards its suppliers on ethical behavior, integrity, professionalism and common business requirements.
Ethical Business Practices
Suppliers shall conduct their business in an ethical manner and act with integrity.
World Recycling Day: Closing the Loop
Transitioning the economy from a linear to a circular approach herculean task – but also an innovation that carries huge potential
12th Expert Forum on Farm Animal Well-Being
The 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts
Raising Questions or Concerns
Supplier must report ethics and compliance concerns that might affect Boehringer Ingelheim.
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
biologicals-development-center
Europe’s largest biotechnology center in Biberach, Germany is the home to three development units.
Expertise in microbial | Bioxcellence | Boehringer Ingelheim
Leverage BioXcellence's expertise in microbial production, providing high-quality, reliable biopharmaceutical manufacturing solutions for your business.
Artrial Fibrillation
Artrial Fibrillation
Keep water clean
Human beings can’t survive without water. Further, the safe production of medicines depends on clean drinking water.
BI Access to Healthcare Strategy_Availability
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Making a difference with data science
Our Head of Central Data Science, Brigitte Fuhr joined the team to make a difference to patients’ lives.
Aseptic filling services | Bioxcellence | Boehringer Ingelheim
Discover top-notch aseptic processing for biopharmaceuticals with our filling services, specializing in freeze-dried products & liquids.
Boehringer Ingelheim 2022 half year results
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Access to Healthcare Strategy Sustainable Access Models
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Large Scale Cell Culture Facility | Bioxcellence | Boehringer Ingelheim
Tour our Large Scale Cell Culture Facility in Vienna, Austria, advancing biopharmaceutical production with cutting-edge cell culture technology.
Plasmid DNA Production | BioXcellence
Discover our range of plasmid DNA production solutions from research to GMP.
Experts in microbial technology | Bioxcellence | Boehringer Ingelheim
Meet one BioXcellence expert in microbial development and manufacturing. Explore our broad commercial experience and development competence.
New biomass power plant Ingelheim
Boehringer Ingelheim produces its own green energy
We’re looking for SAP developers to join our Global IT Department
Are you looking to take the next step in your career? Our global IT department has new SAP developer positions available!
Expectations towards our business partners
We utilize an extensive network of international suppliers for procuring raw materials, intermediates, packaging materials, technical components and services to deliver our innovative medications worldwide.
Our Expectations
We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
Brigitte Fuhr
Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
FOYA_Shanghai
Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”